I gave a talk Wednesday as part of an ethics series here at Duke. Here is one take on my presentation. See if you can spot the Far Side reference!
In response to the New England Journal article I published with Yousuf Zafar and Amy Abernethy, Newsweek chimed in this week with a report on the topic, including some thoughtful commentary from other medical experts. I thought it was worth pointing you towards this article, in part to remind you that Newsweek still exists, and…
Nine to twelve years. That’s about how long most drug companies have to make serious money on new products before their patent protection ends. Then, generic companies enter the fray and prices, typically, plummet. Yet, two decades after coming to market, Herceptin (a drug used to treat breast and stomach cancer) was still priced at…
American healthcare is ridiculously expensive.
KARAN: Though I hope our readers all read your book, for those who haven’t just yet, I want to start with an example that touches on the issues it discusses. I recently got a bad ankle sprain. The following week, I went to a local orthopedic surgeon for it. He was a very old-school doctor; before…
Most men diagnosed with prostate cancer don’t die of the disease. Between 2011 and 2015, 112.6 per 100,000 men per year were diagnosed with prostate cancer in the U.S., but only 19.5 per 100,000 men per year died of the disease over that same period of time. That is still far too many deaths. But the…